concurrent private placement.We have granted the underwriters a 30-day option to purchase up to an additional 540,000 shares of common stock from us at the initial public offering price less the underwriting discounts and
of approved VEGF inhibitors that we are studying in combination with TRC105 have agreed to supply their drug at no cost for use in the applicable clinical trials.The Endoglin Pathway: A Promising Approach to Treating Cancer,AMD and Fibrotic DiseasesWe focus on developing antibodies that target the endoglin receptor.
are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.•We depend in part on NCI to advance clinical development of TRC105 and TRC102 and also depend in part on Case Western to
that are more advanced or effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates.Concurrent Private PlacementNew Enterprise Associates 14, L.P., or NEA, an existing stockholder, has indicated an interest in purchasing up to
models of fibrosis and obtain the supply of TRC205 for our anticipated Phase 1 clinical trials; and (5) the remainder for working capital and other general corporate purposes, including funding the costs of operating as a public company.
candidate, TRC105, will require substantial additional development time and resources before we would be able to apply for or receive regulatory approvals and begin generating revenue from product
development expenses to substantially increase in connection with our ongoing activities, particularly as we advance our clinical programs, including our planned and future clinical trials of TRC105.We estimate that we will receive net proceeds of approximately $40.4 million (or approximately $47.0 million if the underwriters exercise in full their option to purchase
due to lack of financing, it would have a material adverse effect on our business, operating results and prospects.Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on
the prospects for approval of TRC105 as well our stock price would be materially and adversely affected.15Table of ContentsDelays in clinical trials are common and have many causes, and any delay could result in increased costs to us and jeopardize or delay our ability to obtain regulatory
sites by the FDA or other regulatory authorities;•delays in reaching agreement on acceptable terms with prospective clinical trial sites;•delays in obtaining required institutional review board approval at each site;•delays in recruiting suitable patients to participate in a trial;•delays in having patients complete participation in a trial or return for post-treatment follow-up;•clinical sites dropping out of a trial to the detriment of enrollment;•time required to add new clinical sites; or•delays by our contract manufacturers or other third parties to produce and deliver sufficient supply of clinical trial
markets for patients or indications that we are targeting are not as significant as we estimate, we may not generate significant revenue from sales of such products, if approved.18Table of ContentsWe may not receive Fast Track designation for our product candidates from the FDA, or Fast Track designation may not actually lead to a faster development or regulatory
are subject to a number of other risks associated with our dependence on our license agreement with Santen, including:•Santen may not comply with applicable regulatory requirements with respect to developing or commercializing products
under the license agreement, which could adversely impact development, regulatory approval and eventual commercialization of such products;•we and Santen could disagree as to future development plans and Santen may delay initiation of clinical trials or stop a
to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or commercialize our product candidates.Risks Related to Our Intellectual PropertyIf we are unable to obtain or protect intellectual property rights related to our product candidates, we may not be able to compete effectively.We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property
programs, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results.We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability.The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to
claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.If our third party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.Our development activities involve the controlled use of potentially hazardous substances, including chemical and biological
proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed.Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.Our operations, and those of our contractors and consultants, could be subject to earthquakes, power shortages, telecommunications
negative effect on the trading price of our common stock.We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance